|
Market Closed -
Nasdaq Copenhagen
18:20:00 18/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 40.50 DKK | +2.66% |
|
-7.53% | +11.88% |
| 09-11 | Lundbeck's Asedebart Gets US FDA Orphan Drug Designation for Endogenous Cushing's Syndrome | MT |
| 09-11 | Lundbeck wins US orphan drug status for asedebart in Cushing's syndrome | FW |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
Data source:
H. Lundbeck A/S(HLUN B)
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Data source:
H. Lundbeck A/S(HLUN B)
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
Data source:
H. Lundbeck A/S(HLUN B)
EBIT
Dividend / Share (DPS)
Data source:
H. Lundbeck A/S(HLUN B)
Cash or Net Debt
- Stock Market
- Stocks
- HLUN B Stock
- LUN Stock
- Consensus Lundbeck
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
